]>
IRCT201109287660N1 IRCT 2012-11-08 Mashhad University of Medical Sciences Effect of Aspirin in schizophrenia Effect of Aspirin augmentation on cognitive & clinical symptoms of schizophrenic patients 2012-04-03 anticipated 40 Complete https://irct.ir/trial/8128 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 3 schizophrenia. Intervention 1: Case group:Tab Aspirin 500 mg ,BID( Abidi company). Intervention 2: placebo group: tab placebo Aspirin like 500 mg ,BID. <br /> Introduction: schizophrenia is one of the most common psychological diseases. New investigations showed that NSAIDs usage could be helpful in its treatment by preventing PG sanitize with inhibiting cycloxygeniz activation. The aim of this study was to evaluate the affect of adding aspirin to regular schizophrenia treatment.<br /> Methods: in this randomized clinical trial 40 schizophrenia patients who were admitted in Ibn Sina hospital and had the inclusion criteria were entered and fallowed up for 12 weeks. First group had received 1 gram aspirin and second group had received placebo with the same shap and color add on regular treatment of schizophrenia. Patient symptoms and signs and their side effects were compared with SPSS software using mann-whittny and t-test regard to the variables. <br /> Results: patient`s mean age was 8.68± 31.9 year and 88.3 percent (33 patients) of them were male and 17.5%(7 patients) were female. Mean overall PANSS in aspirin group and placebo was 11.76±62.95 and 5.8±56.8in third week and 11.77± 60.15 and 6.63±53.8in sixth weeks and this difference were significant. (P=0.045, P=0.042) digit span and Wechsler showed no differences after intervention. (P>0.05)<br /> Conclusion: adding aspirin to regular schizophrenia treatment could be helpful to control some signs and symptoms and reduce psychopathology.<br />
public Dr. Maryam Tavakoli
Hore Ameli Blvd, Ferdosi Sq.
Mashhad Iran (Islamic Republic of) +98 51 1761 1849 tavakolim881@mums.ac.ir Psychiatric Ibnesina Hospital scientific Dr. Maryam Tavakoli
Hore Ameli Blvd, Ferdosi Sq.
Mashhad Iran (Islamic Republic of) +98 51 1761 1849 tavakolim881@mums.ac.ir Psychiatric Ibnesina Hospital Iran (Islamic Republic of) Inclusion criteria: 1 - Is based on DSM-IV diagnosis of schizophrenia. 2 - The patient or patient's guardian consent to participate. 3 - PANSS score at the beginning of the project is more than 60. 4 - less than 5 years of disease duration and between 3 to 1 episodes. 5 - No physical disease based on clinical examination. 6 - Chronic NSAID is not used. 7 - Not taking corticosteroids. 8 - Not pregnant. 9 - there is no contraindication for aspirin and omeprazole. Exclusion criteria: 1 - Sensitivity to the drug 2 - Patients who choose to be excluded. 3 – Require other drugs. (Anticholinergics and benzodiazepines are excepted) 4 – Where ECT is needed. no limit no limit Both F20.0 Paranoid schizophrenia Placebo Treatment - Drugs Case group:Tab Aspirin 500 mg ,BID( Abidi company) placebo group: tab placebo Aspirin like 500 mg ,BID Cognitive disorders. Timepoint: baseline and 3th,6th,12th weeks. Method of measurement: cognition tests. Clinical symptoms. Timepoint: baseline and 3th,6th,12th weeks. Method of measurement: PANSS. Mashhad University of Medical Sciences Approved 2011-09-18 Mashhad University of Medical Sciences Ghoreishi Building ,Daneshgah Street Mashhad Iran (Islamic Republic of)